Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
Open Access
- 13 October 2010
- journal article
- research article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 8 (1) , 88
Abstract
There is a paucity of information about the molecular perturbations involved in MPM tumor formation. We previously reported that EGFR-TK mutations in MPM were predictive of achieving optimal surgical cytoreduction, but the status of EGFR pathway activation potential of these mutations was not known. Here we present the mutant EGFR activating potential and the matured survival data of the EGFR mutant(mut+) relative to wild type EGFR(mut-) mesothelioma.Keywords
This publication has 29 references indexed in Scilit:
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- Epidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer PatientsClinical Cancer Research, 2006
- Diffuse malignant mesothelioma of the peritoneumCancer, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysisGynecologic Oncology, 2004
- Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancerCancer, 1991